Welcome to our dedicated page for CGNGY news (Ticker: CGNGY), a resource for investors and traders seeking the latest updates and insights on CGNGY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CGNGY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CGNGY's position in the market.
Humanigen (Nasdaq: HGEN) announces that lenzilumab is now available for specific hospitalized COVID-19 patients through the LenzMAP™ Managed Access Program, managed by Clinigen Group. This investigational product is accessible in 17 countries, including the UK and various European nations. The program will provide lenzilumab to patients deemed appropriate by healthcare professionals where local regulations permit. As Humanigen continues to pursue regulatory approvals for lenzilumab, the partnership with Clinigen aims to facilitate access to treatment for those in need.
Humanigen has partnered with Clinigen Group to launch a Managed Access Program (LenzMAP) for their investigational treatment, lenzilumab, aimed at hospitalized COVID-19 patients across 16 European countries. The program allows access on a case-by-case basis where no alternatives are available. Currently, lenzilumab is not authorized in any country, and Humanigen continues to pursue regulatory approvals, including a Marketing Authorization Application with the European Medicines Agency.
Secura Bio announced a distribution agreement with Clinigen Group for COPIKTRA (duvelisib) across 39 European countries, including Germany and the UK, where Secura will promote it directly. COPIKTRA, approved by the European Medicines Agency in May 2021, treats relapsed or refractory Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphoma (FL). The partnership aims to ensure rapid availability and access to this oncology therapeutic for patients in need. Secura Bio is working on reimbursement and commercial launch strategies for the drug in Europe.
FAQ
What is the market cap of CGNGY (CGNGY)?
